NSC 1008 is a selective Ras converting enzyme 1 (Rce1) inhibitor that reduces Rce1 in vitro activity with a human IC50 of 8.9 μM. NSC 1008 demonstrates selectivity for Rce1 by not inhibiting human Ste24 or huamn FTase. NSC 1008 exhibits low cell toxicity, and induces mislocalization of EGFP-Ras from the plasma membrane in cancer cells. NSC 1008 can be used for the research of cancer.

NPD15261 (MI102) is a highly selective MYCN inhibitor. NPD15261 reduces the mRNA and protein levels of MYCN in liver cancer cells, inhibits cell proliferation and colony formation, and induces Apoptosis simultaneously. NPD15261 can be used in liver cancer research.

NLRP3-IN-86 (Compound 8a), a derivative of Songorine, is a potent and selective NLRP3 inflammasome inhibitor. NLRP3-IN-86 can reduce LPS- and Nigericin-stimulated lactate dehydrogenase (LDH) release (IC50 = 2.69 μM in THP-1 cells and 1.75 μ M in J774A.1 cells). NLRP3-IN-86 can inhibit gasdermin D (GSDMD) cleavage and IL-1β secretion. NLRP3-IN-86 can inhibit cell pyroptosis. NLRP3-IN-86 can be used for research of inflammation.

Nitramisole is a nitrobenzene-heterocycle conjugate and microfilaricide. Nitramisole kills microfilariae of Brugia malayi, Dipetalonema viteae and Litomosoides carinii. Nitramisole can be used for the research of filariasis (Brugia malayi, Dipetalonema viteae, Litomosoides carinii infections).

Neuroprotective agent 15 (Compound 3e) is a neuroprotective agent. Neuroprotective agent 15 is a selective butyrylcholinesterase (BChE) inhibitor, with IC50 values of 2.6 and 114.3 μM for BChE and AChE respectively. Neuroprotective agent 15 has cannabinoid CB2 receptor (CB2 receptor) agonistic activity. Neuroprotective agent 15 can reduce cell death, LDH release and Caspase-3/7 activity, and inhibit apoptosis. Neuroprotective agent 15 can reduce the formation of superoxide free radicals, maintain cell morphology, and significantly lower oxidative stress levels. Neuroprotective agent 15 can be used in the research of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

NEP108 is a GID4 E3 ligase-based BRD4 PROTAC degrader, with its DC50 value approximately 3.8 μM. NEP108 has a strong affinity for GID4, with a KD value of 0.22 μM, and the KD value of its trimeric complex is 2.85 μM. NEP108 can be used for cancer research. (Pink: BRD4 ligand ; Blue: Ligands for E3 Ligase ligand ; Black: linker).

Nebracetam (WEB 1881 FU) is an orally active M1 muscarinic receptor agonist. Nebracetam can induce an increase in intracellular Ca2+ concentration, with an EC50 value of 1.59 mM. Nebracetam exhibits neuroprotective activity and the ability to improve cognitive impairment. Nebracetam can be used in the research of neurological diseases such as Alzheimer's disease.

NAT8L-IN-1 is a NAT8L inhibitor with an IC50 value of 0.3 μM. NAT8L-IN-1 can be used for the research of Canavan disease.

N19-0881 (Compound 33) is an orally active, potent and selective KDM5A/5B histone lysine demethylase inhibitor (IC50= 0.013 μM and 0.002 μM, respectively). N19-0881 is promising for research of epigenetically dysregulated tumors (e.g., breast cancer).

N,N-Di-(beta-carboethoxyethyl)methylamine is a PROTAC linker that can be used in the synthesis of PROTACs.

N-(Aminoiminomethyl)-N-methyl-D-alanine is an amino acid derivative that can be used in the research of cancer.

N-(3-Aminopropyl)-N-methylcarbamic acid tert-butyl ester is a PROTAC linker that can be used in the synthesis of PROTACs.

MU262 is a MUS81 inhibitor with an IC50 value of 0.87 μM. MU262 directly inhibits the catalytic activity of MUS81 without interfering with DNA binding, induces genomic instability in tumor cells, and specifically inhibits the HR/BIR repair pathway. The combination of MU262 with Cisplatin significantly enhances the chemotherapeutic killing effect. MU262 serves as a chemical biology tool for studying MUS81 function, and also acts as a lead compound for the development of anticancer therapies that exploit DNA repair defects in cancer cells.

mPEG-DLG (MW 2000) is a PEG-based lipid that can be used to formulate lipid nanoparticles for drug delivery.

Montanastatin is an antitumor agent that can be isolated from the terrestrial actinomycete Streptomyces anulatus. Montanastatin inhibits the growth of various cancer cells. Montanastatin can be used in research related to lymphocytic leukemia, ovarian cancer, brain cancer, renal cancer, lung cancer, colon cancer and melanoma.

ML279 is a potent scavenger receptor, class B, type I (SR-BI) inhibitor. ML279 can inhibit SR-BI-mediated lipid uptake by stabilizing the binding of HDL to SR-BI (EC50 = 0.27 μM). ML279 can be used for the researches of infection and cardiovascular disease, such as atherosclerosis and HCV infection.

mGluR7 antagonist-2 (compound 1) is a potent and selective metabotropic glutamate receptor 7 (mGluR7) allosteric antagonist (IC50 = 20 nM). mGluR7 antagonist-2 shows high selectivity over other mGluRs (mGluR1/2/3/4/5/6/8).

Methyl 3-chlorobicyclo[1.1.1]pentane-1-carboxylate is a PROTAC linker that can be used in the synthesis of PROTACs.

Mer/c-Met-IN-1 is a potent Mer/c-met dual inhibitor with IC50 values of 1 and 19 nM. Mer/c-Met-IN-1 can inhibit cancer cells proliferation, migration and induce apoptosis. Mer/c-Met-IN-1 can be used for the research of cancer, such as colon cancer.

Meglitinide is an ATP-sensitive potassium (KATP) channel inhibitor. Meglitinide exhibits IC50 values of 0.26 μM, 0.53 μM and 1.6 μM against KATP channels containing SUR1, SUR2A and SUR2B, respectively, with a Kd value of 7 μM for both SUR1 and SUR2A, and a Kd value of 8 μM for SUR2B. Meglitinide binds to the SUR1, SUR2A and SUR2B subunits with high affinity to close KATP channels, acting on a binding site shared by all SUR subtypes, and its interaction with SUR1 carrying the S1237Y mutation remains unchanged. Meglitinide is applicable to research related to type 2 diabetes.

MCULE-3064932370 is a covalent and allosteric SUMO E1 (heterodimer of Aos1 and Uba2) inhibitor with IC50 values ranging from 16.66 μM to 2.96 μM. MCULE-3064932370 inhibits SUMOylation of Uba2. MCULE-3064932370 has anti-cancer activity against breast cancer.

M2WJ332 is an inhibitor of the M2 proton channel of the influenza A virus M2S31N mutant M2. M2WJ332 potently inhibits the influenza A virus A/M2-S31N proton channel in Xenopus laevis oocytes, with an IC50 of 16 μM. M2WJ332 completely inhibits plaque formation by the influenza A virus carrying the M2S31N mutant. M2WJ332 is applicable to research related to influenza A virus infection.

LY580276 is an ATP-competitive ALK5 inhibitor with an IC50 of 175 nM. LY580276 inhibits transforming growth factor-β-induced epithelial-mesenchymal transition. LY580276 can be used for cancer research.

LY-326188 is a HIV-1 protease inhibitor, with an IC50 of 0.42 nM. LY326188 exhibits potent protection of HIV-1 infected cells.

LY164846 is an orally active cephalosporin. LY164846 is highly sensitive to Haemophilus influenzae (including Ampicillin-resistant strains) and Moraxella catarrhalis (with MIC90 ≤ 4 μg/mL). LY164846 is generally sensitive to Methicillin-resistant Staphylococcus aureus and Streptococcus (except Enterococcus) (with MIC90: 0.25 - 8 μg/mL), and moderately sensitive to anaerobic bacteria. LY164846 has MBC/MIC ratio to Haemophilus influenzae of ≤ 2, showing bactericidal activity. LY164846 can be used for research on respiratory and skin infections.

LTK-14A, a derivative of Garcinol, is a selective histone butyrylation inhibitor. LTK-14A does not affect acetylation. LTK-14A significantly inhibits the butyrylation of H4K5 and downregulated the expression of proadipogenic genes, thus culminating in abolished adipogenesis. LTK-14A can be used for the study of obesity.

LTD4 antagonist 3 (FK011 hydrochloride) is a LTD4 antagonist. LTD4 antagonist 3 has agonistic activity for PPAR-γ, with a fold-increase of 1.50 at 1 μM and 2.35 at 10 μM. LTD4 antagonist 3 can be used of development of non-steroidal anti-inflammatory drugs (NSAIDs).

ML161 analog 1 (compound 38) is an analog of ML161. ML161 analog 1 is a selective allosteric inhibitor of PAR1 with an IC50 of 1.68 μM.

LSD1-IN-41 (compound 7) is a potent and selective LSD1 inhibitor. LSD1-IN-41 can be used for diffuse intrinsic pontine glioma (DIPG) research when combined with HDAC inhibitors.

LP-911888 is an orally active ACSL5/ACSL1 inhibitor, with IC50 values of 1 nM and 3 nM against mouse and human ACSL5, and IC50 values of 2 nM and 9 nM against mouse and human ACSL1, respectively. LP-911888 inhibits intestinal triglyceride uptake; it also reduces body weight and food consumption in diet-induced obese mice, and delays gastric emptying by activating the ileal brake pathway. LP-911888 can be used in studies of diet-induced obesity.